Alteotech Moves Forward With KOSPI Relisting Plan

According to Newsis on July 12, Alteotech, a leading KOSDAQ-listed biopharmaceutical company, is advancing its relisting to KOSPI. The company passed a shareholder resolution in December 2025 to transfer its listing to Korea's main bourse. Alteotech aims to leverage its distinctive drug development platform to maximize enterprise value and secure inclusion in major indices such as the KOSPI 200.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments